Chemical-genetic interactions -observed when the treatment of mutant cells with chemical 21 compounds reveals unexpected phenotypes -contain rich functional information linking 22 chemical-genetic and genetic interaction screens now underway in multiple species including 61 human cells, the method described here can be generally applied to enable the characterization of 62 compounds' effects across the tree of life. 63
compounds to their cellular modes of action. To systematically identify these interactions, an 23 array of mutants is challenged with a compound and monitored for fitness defects, generating a 24 chemical-genetic interaction profile that provides a quantitative, unbiased description of the 25 cellular function(s) perturbed by the compound. Genetic interactions, obtained from genome-26 wide double-mutant screens, provide a key for interpreting the functional information contained 27 in chemical-genetic interaction profiles. Despite the utility of this approach, integrative analyses 28 of genetic and chemical-genetic interaction networks have not been systematically evaluated. We 29 developed a method, called CG-TARGET (Chemical Genetic Translation via A Reference 30
Genetic nETwork), that integrates large-scale chemical-genetic interaction screening data with a 31 genetic interaction network to predict the biological processes perturbed by compounds. CG-32
TARGET compared favorably to a baseline enrichment approach across a variety of 33 benchmarks, achieving similar accuracy while substantially improving the ability to control the 34 false discovery rate of biological process predictions. We applied CG-TARGET to a recent 35 screen of nearly 14,000 chemical compounds in Saccharomyces cerevisiae, integrating this 36 dataset with the global S. cerevisiae genetic interaction network to prioritize over 1500 37 compounds with high-confidence biological process predictions for further study. Upon 38 investigation of the compatibility of chemical-genetic and genetic interaction profiles, we 39 observed that one-third of observed chemical-genetic interactions contributed to the highest-40 confidence biological process predictions and that negative chemical-genetic interactions 41 overwhelmingly formed the basis of these predictions. We present here a detailed 42 characterization of the CG-TARGET method along with experimental validation of predicted 43 biological process targets, focusing on inhibitors of tubulin polymerization and cell cycle 44 progression. Our approach successfully demonstrates the use of genetic interaction networks in 45 the functional annotation of compounds to biological processes. 46
Author Summary

47
Understanding how chemical compounds affect biological systems is of paramount 48 importance as pharmaceutical companies strive to develop life-saving medicines, governments 49
seek to regulate the safety of consumer products and agrichemicals, and basic scientists continue 50 to study the fundamental inner workings of biological organisms. One powerful approach to 51 characterize the effects of chemical compounds in living cells is chemical-genetic interaction 52 screening. Using this approach, a collection of cells -each with a different defined genetic 53 perturbation -is tested for sensitivity or resistance to the presence of a compound, resulting in a 54 quantitative profile describing the functional effects of that compound on the cells. The work 55 presented here describes our efforts to integrate compounds' chemical-genetic interaction 56 profiles with reference genetic interaction profiles containing information on gene function to 57 predict the cellular processes perturbed by the compounds. We focused on specifically 58 developing a method that could scale to perform these functional predictions for large collections 59 of thousands of screened compounds and robustly control the false discovery rate. With 60
Introduction
Inhibitor Set (the "NCI/NIH/GSK" screen) [13] . The compounds in the RIKEN screen consisted 125 primarily of natural products and natural product derivatives -most of which were previously 126 uncharacterized -and ~200 approved drugs and chemical probes, a subset of which we used to 127 assess the performance of CG-TARGET as their modes of action in yeast are well-characterized. 128
The compounds in the NCI/NIH/GSK screen were more studied -having been tested against the 129 NCI-60 cancer cell line panel (the NCI collections), tested in clinical trials (the NIH Clinical 130 Collection) or designed and characterized as inhibitors against human kinases (GSK) -but many 131 of these compounds' specific modes of action remain uncharacterized. The final datasets 132 consisted of 8418 chemical-genetic interaction profiles from the RIKEN screen and 3565 from 133 the NCI/NIH/GSK screen, which were obtained using a diagnostic set of approximately 300 134 haploid gene deletion mutants that were optimally selected to capture most of the information in 135 the complete S. cerevisiae non-essential deletion collection [11, 14] . Both datasets also contained 136 a large set of experimental control profiles (5724 and 2128 for the RIKEN and NCI/NIH/GSK 137 screens, respectively), in which the yeast were only treated with the solvent control (DMSO). 138
Each profile contains z-scores that reflect the deviation of each strain's observed fitness from 139 expected fitness in the presence of a compound. 140
Genetic interaction profiles were obtained from a recently assembled, genome-wide 141 compendium of genetic interaction profiles in S. cerevisiae [5] . These profiles were generated by 142 systematically constructing and analyzing the fitness of haploid double mutant strains and consist 143 of epsilon scores that reflect the deviation of each double mutant's observed fitness from that 144 expected given the single mutant fitness values, assuming a multiplicative null model [15] . The 145 construction of each profile involved crossing the mutant for the "query" gene into a genome-146 wide array of mutants, and we mapped the query genes to Gene Ontology biological process 147 terms [16, 17] to define the bioprocess targets of compounds. Profiles were filtered to the ~35% 148 with the highest signal (see Materials and Methods). 149
Predicting perturbed bioprocesses from chemical-genetic interaction profiles 150 We developed CG-TARGET (Chemical Genetic Translation via A Reference Genetic 151 nETwork) to predict the biological processes perturbed by compounds in our recently-generated 152 dataset of ~12,000 chemical-genetic interaction profiles (Fig 1) . CG-TARGET requires three 153 input datasets: 1) chemical-genetic interaction profiles; 2) genetic interaction profiles; and 3) a 154 mapping from the query genes in the genetic interaction profiles to gene sets representing 155 coherent bioprocesses. Predicting the bioprocesses perturbed by a particular compound involves 156 four distinct steps. First, a control set of resampled chemical-genetic interaction profiles is 157 generated, each of which consists of one randomly-sampled interaction score per gene mutant 158 across all compound treatment profiles in the chemical-genetic interaction dataset; these profiles 159 thus provide a means to account for variance in each mutant strain observed upon treatment with 160 bioactive compound but not upon treatment with experimental controls (DMSO with no active 161 compound). Second, scores reflecting both the strength of each compound's chemical-genetic 162 interaction profile and its similarity to the profile of each gene mutant are obtained by computing 163 an inner product between all chemical-genetic interaction profiles (comprising compound 164 treatment, experimental control, and random profiles) and all L2-normalized query genetic 165 interaction profiles. Third, these "gene-level" prediction scores are aggregated into bioprocess 166 predictions; a z-score and empirical p-value for each compound-bioprocess prediction are 167 obtained by mapping the gene-level prediction scores to the genes in the bioprocess of interest 168 and comparing these scores to those from shuffled gene-level prediction scores and to 169 distributions of the scores derived from experimental control and resampled profiles. Finally, the 170 false discovery rates for these predictions are estimated by comparing, across a range of 171 significance thresholds, the frequency at which experimental control and randomly resampled 172 profiles predict bioprocesses versus that of compound treatment profiles (see Materials and 173 Methods). 174
Application to and evaluation on large-scale chemical-genetic interaction data
175
To provide a baseline method for benchmarking the performance of CG-TARGET on these 176 large screens, we implemented a simple, enrichment-based approach for predicting bioprocess-177 level targets. The enrichment-based approach was designed to predict bioprocess-level targets by 178 testing for the enrichment of GO biological processes among the top-n gene-level prediction 179 scores for each compound. For the following comparisons, CG-TARGET was compared to top-180 20 enrichment, which showed the best overall performance across a range of values of n ( Fig  181   S1 ). 182
We applied CG-TARGET to the RIKEN and NCI/NIH/GSK chemical-genetic interaction 183 screens, identifying 848 out of 8418 compounds (10%) from the RIKEN screen and 705 of 3565 184 compounds (20%) from the NCI/NIH/GSK screen with at least one prediction that achieved false 185 discovery rates of 25 and 27%, respectively (referred to as "high-confidence" compounds and predictions) ( Table 1 , Fig 2) . In all cases, the false discovery rates derived from resampled 187 profiles were more conservative than those derived from experimental controls, suggesting that 188 some sources of variance in each gene mutant's interaction scores arose only upon treatment 189 with compound and therefore could not be corrected using only solvent controls. Focusing on the 190 results from the RIKEN screen, CG-TARGET substantially outperformed the baseline method 191 with regard to the number of compounds that possessed at least one high-confidence bioprocess 192 prediction (FDR ≤ 25%). Compared to the 848 high-confidence compounds identified by TARGET, top-20 enrichment only identified seven compounds that met this confidence 194 threshold, and zero with a false discovery rate less than 21% ( Fig 3A) . 195 CG-TARGET was also benchmarked against the baseline method using two different 196 measures of prediction accuracy. The first accuracy-based evaluation was performed on genetic 197 interaction profiles with added noise, which provided a means to both simulate chemical-genetic 198 interaction profiles and annotate them with gold-standard GO biological process annotations for 199 evaluation. For the second accuracy-based evaluation, we curated a set of gold-standard 200 compound-bioprocess annotations from the literature for 35 compounds from the RIKEN screen 201 and evaluated the ranks of the gold-standard bioprocesses within each compound's list of 202 bioprocess predictions. 203 CG-TARGET performed comparably to the best-performing enrichment-based methods 204 using our measures of accuracy. This is first shown in the evaluation of these methods' 205 respective abilities to predict a gold-standard annotated bioprocess as the top prediction for each 206 simulated chemical-genetic interaction profile. Specifically, CG-TARGET performed nearly as 207 well as the top-20 enrichment-based method across both low and high recall values ( Fig 3B) . 208
Both methods captured a gold-standard annotation as the top predicted bioprocess for 209 approximately 34% of the simulated compounds (33.4% and 35.6% for CG-TARGET and top-20 210 enrichment, respectively), which represented more than a 22-fold enrichment over the 211 background expectation of 1.5% (the average number of gold-standard bioprocess annotations 212 per simulated compound divided by the number of bioprocesses). 213
Secondly, for the 35 gold-standard compounds with known target bioprocesses, we observed 214 that both methods captured the gold-standard bioprocess for 6 and 21 (out of 35) compounds 215 above ranks of 2 and 40 (out of 1329), respectively, with slightly decreased performance for CG-216 TARGET between these rank thresholds ( Fig 3C, Table 2 ). The significance of these rank values 217 was evaluated by randomizing the order of each compound's bioprocess predictions 10,000 218 times and recalculating the ranks. Both methods achieved similar results in this respect, with CG-219 TARGET and the top-20 enrichment method respectively identifying 22 and 21 gold-standard 220 compounds with significantly better ranks than the random expectation. CG-TARGET and top-221 20 enrichment also performed similarly when comparing the "effective rank" of each 222 compound's gold-standard bioprocess, with CG-TARGET and top-20 enrichment respectively 223 identifying 20 and 22 compounds for which the gold-standard or a closely-related bioprocess 224 achieved a rank of 5 or better. 225
Given that the main performance advantage of CG-TARGET occurred in the context of 226 controlling the false discovery rate, we conclude that the issues with simple enrichment-based 227 approaches primarily emerge not when predicting the most likely perturbed bioprocess for any 228 single compound but when comparing the strength and significance of bioprocess predictions 229 across compounds to prioritize compounds from a large-scale chemical-genetic interaction 230 screen. The aforementioned rank-based analysis of 35 gold-standard compound-bioprocess 231 annotations supports this assertion, as none of the 21 significantly-ranked annotations predicted 232 by top-20 enrichment passed the high-confidence threshold (FDR ≤ 25%), while 16 of the 22 233 significantly-ranked annotations predicted by CG-TARGET did so (Table 2) . This difference 234 between CG-TARGET and enrichment-based methods likely emerges from the ability of weak 235 chemical-genetic interaction profiles to generate strong, statistically significant predictions in the 236 absence of methods (such as CG-TARGET) that account for general signals that arise upon 237 treatment with bioactive compound -especially if these signals are amplified through their 238 similarity to a large cluster of profiles in the genetic interaction network. Thus, the substantially 239 superior ability of CG-TARGET to control the false discovery rate relative to the enrichment-240 based approach is a critical quality in the context of large-scale, systematic compound screens. 241
Characterizing performance with respect to individual bioprocess terms
242
In addition to benchmarking CG-TARGET's ability to prioritize gold-standard annotated 243 bioprocesses for specific compounds, we also benchmarked its ability to prioritize compounds 244 that perturb specific bioprocesses. Specifically, each GO term was evaluated based on the ranks 245 of the predictions for the simulated chemical-genetic interaction profiles derived from genes 246 annotated to that GO term. The 100 best-performing terms represented a diversity of 247 bioprocesses related to the proteasome, glycolipid metabolism, DNA replication and repair, replication and division checkpoints, RNA splicing, microtubules, Golgi and vesicle transport, 249 and chromatin state ( Fig S2) . In contrast, the 100 worst-performing terms were bioprocesses 250 primarily related to carbohydrate, nucleotide, and coenzyme/cofactor metabolism, as well as the 251 mitochondria, transmembrane transport, and protein synthesis and localization ( Fig S3) . The 252 best-performing terms were also significantly smaller than the worst-performing ones (8 and 35 253 genes on average, respectively; rank-sum p-value < 2.2 ´ 10 -16 ), which, given the fact that we 254 would expect the power to increase with gene set size assuming the corresponding set was still 255 functionally coherent, suggests that our method identifies functionally specific signal. 256
Interestingly, the relatively poor performance of many metabolism-related bioprocess terms may 257 result from the fact that the chemical-genetic and genetic interaction screens were both 258 performed in relatively rich medium, precluding analysis of condition-specific phenotypes for 259 genes only required for growth in minimal medium. While the set of best-performing terms did 260 include a diverse range of bioprocesses, the possibility of "blind spots" should always be 261 considered when interpreting the predictions made by CG-TARGET, as they may lead to false 262 negative results that either exclude interesting compounds (e.g. those whose primary modes of 263 action affect carbohydrate metabolism) or mask potential side effects of compounds whose 264 primary modes of action are more easily observed by this method. 265 The prediction of perturbed protein complexes offers the opportunity to enhance the 268 specificity of GO biological process predictions (especially for overly-general bioprocess terms) 269 and investigate functional space not accessible by bioprocess annotations. As such, we 270 investigated the potential to expand the use of CG-TARGET to the prediction of perturbed 271 protein complexes. When CG-TARGET was applied to predict protein complex targets for the 272 RIKEN screen data, 714 compounds were identified with at least one high-confidence (FDR ≤ 273 25%) complex prediction, 604 of which also occurred in our original set of RIKEN compounds 274 with high-confidence bioprocess predictions. Similar, but not completely overlapping, sets of 275 genes (Jaccard index > 0.2) contributed to the top 5 of both bioprocess and protein complex 276 predictions for more than one third of these compounds (219; 36%); this suggested that the two 277 standards possessed both shared and complementary functional information that could be used to 278 improve predictions. 279
Application of CG-TARGET to protein complexes refines functional specificity of
We observed that protein complex predictions narrowed down less-specific bioprocess terms 280 and enabled predictions in places where bioprocess annotations were sparser. To assess the 281 ability to refine bioprocess prediction specificity, we mapped each protein complex to the 282 childless bioprocess terms that completely encompassed them and looked for substantial 283 improvements in prediction strength from the bioprocess to its protein complex "child." We 284 observed several instances in which bioprocess predictions with FDR > 25% (not high 285 confidence) could be converted to high-confidence predictions by refining the bioprocess term to 286 a constituent protein complex. For example, we saw substantial gains for the following 287 bioprocess-to-complex combinations (sizes in parentheses): "mRNA polyadenylation" 288 (bioprocess, not high confidence; size 8) to "mRNA cleavage factor matrix" (complex, high 289 confidence; size 4); "cytoplasmic translation" (51) to "cytoplasmic ribosomal large subunit" 290 (24); "vacuolar acidification" (14) to "H + -transporting ATPase, Golgi/vacuolar" (5); and 291 "regulation of fungal-type cell wall organization" (8) to PKC pathway" (4) ( Table S1 ). 292
Importantly, 27 of the 110 compounds with high-confidence protein complex but not bioprocess 293 predictions achieved their high-confidence status purely based on protein complex predictions 294 that enhanced the specificity of a non-high-confidence, overlapping bioprocess prediction. 295
Additionally, a separate set of 22 out of 110 compounds achieved high-confidence status based 296 solely on predictions to protein complexes that did not strongly overlap with any bioprocesses 297 (Jaccard < 0.2), demonstrating that the current set of protein complex annotations enabled 298 predictions in functional space that was not well captured by a GO biological process term. 299
Assessing the compatibility of chemical-genetic and genetic interaction profiles
300
Our evaluations of CG-TARGET support the premise of the method that genetic interaction 301 profiles can be used as a tool to interpret chemical-genetic interaction profiles. However, we 302 sought to better understand the extent to which these two types of profiles actually agree with 303 one another, and if their systematic differences could shed light on the limits of the core 304 assumption behind our method (i.e. that chemicals mimic the interaction profiles of their genetic 305 targets). To investigate the compatibility of chemical-genetic and genetic interaction profiles, we 306 quantified the contribution of individual gene mutants in the chemical-genetic interaction 307 profiles to the prediction of individual bioprocesses. For a single compound and predicted 308 bioprocess, these "importance scores" were obtained by 1) computing a mean genetic interaction 309 profile across all L2-normalized query genetic interaction profiles that possessed an inner product 310 of 2 or higher with the chemical-genetic interaction profile and mapped to the predicted 311 bioprocess, and 2) computing the Hadamard product (elementwise multiplication) between this 312 mean genetic interaction profile and the compound's chemical-genetic interaction profile. Each 313 score could have been positive, indicating agreement in the sign of chemical-genetic and genetic 314 interactions for a gene mutant, or negative, indicating that the interactions did not agree for that 315 gene mutant. As such, the importance scores summarized the concordance between chemical-316 genetic and genetic interaction profiles, conditioned on an individual compound and a perturbed 317 bioprocess of interest. 318
We use the prediction of NPD4142, a compound from the RIKEN Natural Product 319 Depository, to the "mRNA transport" bioprocess to illustrate how the overlap between chemical-320 genetic and genetic interactions led to bioprocess predictions ( Fig 4A) . A qualitative examination 321 revealed that, indeed, NPD4142 possessed a pattern of chemical-genetic interactions similar to 322 the genetic interactions for the query genes annotated to mRNA transport. More quantitatively 323 and as expected, we observed that the contribution of each gene mutant to a bioprocess 324 prediction depended on the strength of its chemical-genetic interaction with NPD4142 and the 325 number and intensity of its genetic interactions with the mRNA transport query genes. Chemical-326 genetic interactions with mutants of POM152, NUP133, and NUP188, which encode 327 components of the nuclear pore that facilitate import and export of molecules such as mRNA, 328
were the most important, followed by interactions with mutants in the Lsm1-7-Pat1 complex, 329 which is involved in the degradation of cytoplasmic mRNA. 330
Using this approach to assess the importance of individual mutants in the chemical-genetic 331 profile, we globally analyzed the contribution of chemical-genetic interactions to each 332 compound's top bioprocess prediction ( Fig 5) . We performed this analysis twice: first, on all 333 HCS compounds, and second, on a diverse subset of 130 compounds to correct for potential 334 functional biases in the full set [11] . We present here the results from the 130-compound subset, 335 although the results for the full set were qualitatively similar. For each compound, an average of 336 42% of its chemical-genetic interactions contributed to its top bioprocess prediction (chemical-337 genetic interaction cutoff ± 2.5, importance score cutoff +0.1) -a fraction that increased 338 substantially (to 78%) when limiting the analysis to each compound's strong interactions that 339 contributed strongly (chemical-genetic interaction cutoff ± 5, importance score cutoff +0.5).
Overall, we observed that more than one-third of chemical-genetic interactions (1112 / 3129) 341 contributed to a top bioprocess prediction (chemical-genetic interaction cutoff ±2.5; importance 342 score cutoff +0.1). Strikingly, negative chemical-genetic interactions much more frequently 343 contributed to a bioprocess prediction: approximately one-half (1071 / 2112) of negative 344 chemical-genetic interactions contributed as compared to only ~4% (41 / 1017) of positive 345 chemical-genetic interactions at the same cutoff. Furthermore, we observed differences in how 346 the signs within chemical-genetic and mean genetic interaction profiles could disagree with each 347 other despite the global profile similarity that led to bioprocess prediction, with positive 348 chemical-genetic interactions contributing negatively to bioprocess predictions (importance score 349 cutoff < -0.1) over 10 times more frequently than negative interactions (1.9% vs. 0.14%). This 350 trend of negative chemical-genetic interactions supporting strong bioprocess predictions was 351 even more pronounced when restricting this analysis to strong interactions (chemical-genetic 352 interaction cutoff ±5; importance score cutoff +0.5), where negative interactions comprised 353 essentially the entire set of contributing chemical-genetic interactions (219 / 220, 99.5%). These 354 observations were also supported by analyses in which we predicted perturbed bioprocesses 355 using only negative or positive chemical-genetic interactions, finding that negative chemical-356 genetic interactions were the primary drivers of bioprocess predictions and overwhelmingly 357 responsible for their accuracy [11] . We conclude that negative interactions in chemical-genetic 358 interaction profiles contain the large majority of the functional information necessary to predict 359 modes of action. 360
Negative chemical-genetic interactions also contained information specific to chemical 361 perturbations. Specifically, we identified nine mutant strains that exhibited strong negative 362 chemical genetic interactions (z-score < -5) yet were enriched for a lack of contribution 363 (importance score < 0.1) to bioprocess predictions (hypergeometric test, Benjamini-Hochberg 364 FDR ≤ 0.05; shaded region of Fig 5) . Manual inspection of these mutants revealed connections 365 to the high osmolarity glycol (HOG) pathway, cell polarity (cytoskeletal actin polarization, 366 kinetochore and chromosome segregation), and other stress response mechanisms (Table S2 ). As 367 the HOG pathway is important for the cellular response to high osmolarity and other stresses 368 [18] [19] [20] , and repolarization of the cytoskeleton is required for cells to adapt and continue 369 dividing after stress [21, 22] , we hypothesize that many of these overrepresented mutants interact 370 negatively with compounds due to an impaired ability to respond to external stress. This 371 chemical perturbation-specific information may complement or even completely obscure the 372 chemical-genetic signature of a compound's primary mode of action, potentially complicating 373 the interpretation of chemical-genetic interaction profiles using a genetic interaction network. 374
We compared the concordance of chemical-genetic and genetic interaction profiles across 375 multiple compounds predicted to the same bioprocess, revealing that some bioprocesses were 376 predicted by homogenous sets of chemical-genetic interaction profiles while others were much 377 more heterogeneous despite their predicted targeting of the same bioprocess. For example, 378 predictions made to the "CVT pathway" (FDR < 1%) depended almost entirely on a suite of 379 strong negative chemical-genetic interactions with ARL1, ARL3, and ERV13, with contributions 380 from IRS4 and COG8 ( Fig 4B) . This uniformity in the prediction of a bioprocess is contrasted by 381 the diversity of profiles captured within "tubulin complex assembly" predictions ( Fig 4C) . 382
Compounds with top predictions to this term could potentially be partitioned into three classes, 383 divided according to strong contributions from: 1) CIN1/TUB3, PAN3/CIN4, and the SWR1 384 complex (known tubulin polymerization inhibitors Benomyl and Nocodazole); 2) CIN1/TUB3 385 and DSE2 (NPD4098 and NPD2784); or 3) only CIN1/TUB3 (all remaining compounds except 386 NPD4619). Interestingly, the structures of the compounds in each of the former two groups are 387 distinct from those in the other groups, suggesting that the observed diversity in these 388 compounds' functional profiles is mechanistically derived from their structures. 389
Experimental validation of compound-bioprocess predictions
390 Phenotypic analysis of cell cycle progression. The genes and pathways that govern the cell 391 cycle are highly conserved throughout eukaryotes, enabling researchers to infer from yeast how 392 cells in higher organisms integrate internal and external signals to decide when to divide [23] . As 393 such, compounds that inhibit the progression of the cell cycle in yeast may enable a better 394 understanding of the eukaryotic cell cycle or even form the basis for new therapeutic approaches 395 for cancer, in which the cell division cycle is dysregulated [24, 25] . We observed that compounds 396 from the RIKEN Natural Product Depository were enriched for predictions to cell cycle-related 397 bioprocesses [11], especially to the "mitotic spindle assembly checkpoint" that occurs at the 398 beginning of M phase. After manual inspection of these compounds' chemical-genetic 399 interaction profiles, we selected 17 to test if our predictions validated experimentally. 400
Specifically, we looked for increases in the percentage of cells in the G2 phase of the cell cycle (via fluorescence-activated cell sorting) and two budding phenotypes (bud size and % cells with 402 large buds) for yeast treated with compound, together indicative of arrest at the G2/M checkpoint 403 of the cell cycle ( Fig 6A-C) . Indeed, 6 of the 17 selected compounds induced increases in all 404 phenotypes, while zero out of 10 bioactive control compounds (with high-confidence predictions 405 to bioprocesses not related to cell cycle signaling and progression) induced increases in any of 406 these phenotypes (p < 0.05, one-sided Fisher exact test). As compounds can activate the G2/M 407 checkpoint in multiple ways (e.g. induction of DNA damage, inhibition of chromosome 408 segregation), the set of compounds with spindle assembly checkpoint predictions can serve as a 409 resource for studying the diversity of mechanisms by which cell cycle progression is arrested at 410 this checkpoint and which of these may have therapeutic potential. In addition to our study of 411 G2/M checkpoint-activating compounds, we also selected two compounds with high-confidence 412 predictions to the term "cell-cycle phase" (mutually exclusive with mitotic spindle assembly 413 checkpoint), one of which (NPD7834) was observed to arrest cells in G1 phase ( Fig 6A-C) . 414
Inhibition of tubulin polymerization. Compounds that disrupt microtubules are useful for 415 studying cell organization and division and remain promising candidates as antitumor agents 416
[26-28]. As such, we focused on all compounds with the strongest predictions to "tubulin 417 complex assembly" (FDR < 1%) and tested them for activity in an in vitro, mammalian (porcine) 418 tubulin polymerization assay ( Fig 6D) . Like the previous validation experiment, a negative 419 control set of compounds was selected at random to contain high-confidence compounds 420 (bioprocess predictions with FDR ≤ 25%) whose predictions were not related to microtubule 421 assembly or related bioprocesses. We observed that the novel compound NPD2784 strongly 422 inhibited tubulin polymerization, nearly as well as the drug nocodazole and more strongly than 423 the microtubule probe benomyl. In addition, the entire set of compounds predicted to perturb 424 tubulin complex assembly showed significantly increased inhibition of tubulin polymerization 425 when compared to the negative control compounds (p < 0.006, Wilcoxon rank-sum test). 426
Strikingly, all previously-uncharacterized members of this set would not have been discovered 427 using a structure similarity-based approach, as the highest structural similarity between any NPD 428 compound and six compounds representative of major classes of microtubule-perturbing agents 429 did not exceed 0.25 ( Fig 6E) [29]. However, we did observe that structural similarity was 430 predictive of the top 20% of chemical-genetic profile similarities among the compounds selected 431 for validation (AUPR = 0.43 vs. 0.2 for a random classifier), suggesting that their slight 432 differences in function inside the cell are influenced by their structures and that further 433 exploration of compounds with similar structures may yield even more tubulin polymerization 434 inhibitors. With this experimental validation, we have demonstrated the ability of CG-TARGET, 435 and a genetic interaction network in general, to capture a shared mode of action across diverse 436 compounds that can be biochemically-validated. Furthermore, we note that this validation was 437 achieved with a mammalian tubulin assay, demonstrating the power of yeast chemical genomics 438 coupled with CG-TARGET to predict modes of action that translate broadly to other species, 439
including mammalian systems. 440
Discussion
441
The scaling of chemical-genetic interaction screens from tens or hundreds of compounds to 442 tens of thousands of compounds has provided the opportunity, and the necessity, to develop 443 better methods for interpreting the interaction profiles and prioritizing high-confidence 444 compounds. We developed a method, CG-TARGET, to address this need and used it to predict 445 perturbed biological processes for the nearly 14,000 compounds interrogated in our recent high-446 throughput chemical-genetic interaction screen [11] . CG-TARGET demonstrated the ability to 447 recapitulate known compound function while controlling the false discovery rate, enabling high-448
confidence mode-of-action prediction for 1522 largely uncharacterized compounds [11] , which 449 we prioritized for further study. Further investigation of the profiles from these high-confidence 450 compounds revealed broad compatibility between chemical-genetic and genetic interaction 451 profiles, the overwhelming basis of which was contributed by negative chemical-genetic 452 interactions. Some interesting exceptions to this compatibility were observed for genes that may 453 reduce the ability of compounds to deal with external stress. We experimentally confirmed the 454 accuracy of our predictions for two different classes of previously uncharacterized compounds -455 tubulin polymerization inhibitors and mitotic checkpoint inhibitors -and demonstrated the 456 ability of CG-TARGET to predict activity against a conserved mammalian target. In addition to 457 these findings, the predictions made using CG-TARGET were experimentally validated on a 458 large scale for 67 compounds in an orthogonal cell cycle assay and revealed insights into the 459 distribution of functions perturbed by compounds in large compound libraries, which is 460 described in the companion paper [11] . 461
In high-throughput chemical screens, it is important to prioritize the compounds most likely 462 to demonstrate desired biological activity in further studies. While CG-TARGET and a baseline, 463 enrichment-based approach achieved similar performance in ranking gold-standard bioprocess 464 annotations for simulated chemical-genetic interaction profiles and compounds with known 465 modes of action, CG-TARGET outperformed the baseline approach with regard to controlling 466 the false discovery rate, discovering two orders of magnitude more compounds at a false 467 discovery rate of 25%. As a result, CG-TARGET was substantially better than the baseline 468 approach at accurately annotating, with high confidence, compounds with known modes of 469 action. The fact that our genetic interaction-based predictions were both accurate and achieved 470 appropriate control of the false discovery rate is important, as the global genetic interaction 471 network provides a much more comprehensive and unbiased resource than the limited set of gold 472 standard compounds for predicting bioprocesses perturbed by compounds. In addition, predicting 473 compound function at the bioprocess level allowed functional characterization of compounds 474 whose effects in cells did not occur via direct action on protein targets (e.g. damaging DNA or 475 disrupting cell membranes,), which would have been impossible with a method based purely on 476 comparing chemical-genetic and genetic interaction profiles. 477
While we demonstrated the ability to predict perturbed bioprocesses for compounds and 478 prioritize the highest-confidence predictions, many further steps are required to identify lead 479 compounds and ultimately develop molecular probes or pharmaceutical agents. Perturbing a 480 biological process does not necessarily require perturbing a specific protein target, and as such, 481 further refinements to our methods are needed to identify specific molecular targets (i.e. 482 proteins) and prioritize the compounds most likely to perturb a small number of defined targets 483 in the cell. We envision the use of multiple functional standards with CG-TARGET, such as 484 biological processes and protein complexes as demonstrated here, to improve our ability to 485 predict compound mode of action at different levels of resolution and predict the compounds that 486 exert specific versus general effects in the cell. Different modes of chemical-genetic interaction 487 screening can provide support in this endeavor, as heterozygous diploid mutant strains, gene 488 overexpression strains, and/or spontaneous compound-resistant mutants can provide evidence for 489 the direct, essential cellular target(s) of a compound [1, 7] . Regardless of the limitations in 490
predicting precise molecular targets, information about the bioprocesses perturbed by an entire 491 library would be useful in selecting the compounds most amenable to activity optimization and 492 off-target effect minimization in the development of a pharmaceutical agent or molecular probe. 493
The approach described here can be translated to work in other species for which obtaining 494 functional information on compounds would be useful. interaction network as exists in S. cerevisiae, as our work highlights the ability of a diagnostic set 501 of gene mutants to capture functional information and predict perturbed biological processes. 502
From the discovery of urgently-needed antibacterial or antifungal agents, to the treatment of 503 orphan diseases or a better understanding of drug and chemical toxicity, the combination of 504 chemical-genetic and genetic interactions in a high-throughput format, with appropriate analysis 505 tools, offers a means to achieve these goals via the discovery of new compounds with previously 506 uncharacterized modes of action. 507 Genetic interaction data. The genetic interaction dataset was obtained from a recently 521 assembled S. cerevisiae genetic interaction map [5, 9] ; it was filtered to contain quantitative 522 fitness observations for double mutants obtained upon crossing 1505 high-signal query gene 523 mutants into an array of 3827 array gene mutants. The procedure for selecting the 1505 high-524 signal query genes out of the larger pool of 4382 is described in [11] . Briefly, each query profile 525 was required to possess at least 40 significant genetic interactions, a sum of cosine similarity 526 scores with all other query profiles greater than 2, and a sum of inner products with all other 527 query profiles greater than 2. The final genetic interaction dataset used in this study was filtered 528 to contain only array strains present in the chemical-genetic interaction datasets. 529 Gold-standard compound-process annotations. Biological processes were assigned to 35 542 primarily antifungal compounds with chemical-genetic interaction profiles in the RIKEN dataset, 543 based on known information about their modes of action. Bioprocess terms were selected to be 544 specific to the compounds' modes of action where applicable. 545
Materials and Methods
GO Biological Processes and protein complexes.
Predicting perturbed bioprocesses from chemical-genetic interaction profiles
546
Our method to predict biological processes perturbed by compounds is briefly summarized in 547 the recent study from which the chemical-genetic interaction profiles were obtained [11], and is 548 more formally described here. Fig S4 provides a schematic representation of the method. 549
Notation. We first clarify here a few uses of mathematical notation that simplify the explanation 550 of the methods. First, the i th row and column vectors of a matrix A are denoted as Ai,* and A*,i, 551 respectively. Second, the Iverson bracket is used to convert logical propositions into values of 1 552 or 0, depending on if the logical proposition is true or false, respectively. This is used to simplify 553 expressions for counting the number of elements in a vector that meet given criteria. Specifically, 554 for a logical proposition L, the definition of the Iverson bracket is: 555
Data representation and overview of procedure. CG-TARGET requires chemical-genetic 558 interaction profiles, genetic interaction profiles, and a mapping from genes to biological 559 processes, all of which will be represented as matrices here (illustrated in Fig S4, along with  560 example matrix dimensions and a graphical description of the bioprocess prediction procedure). 561
For chemical-genetic interaction matrices, let us consider an nm x nα matrix of compound 562 treatment profiles Cα, an nm x nβ matrix of negative experimental control profiles Cβ, and an nm x 563 nγ matrix of resampled profiles Cγ, where nm is the number of mutant strains in each chemical-564 genetic interaction profile, nα is the number of profiles derived from treatment with compound, 565 nβ is the number of profiles derived from negative experimental controls, and nγ is the number of 566 chemical-genetic interaction profiles resampled from Cα. The matrix G of genetic interaction 567 profiles is nm x nq and the binary matrix B of gene to bioprocess mappings is nq x np, where nm is 568 the number of mutant strains in the chemical-genetic interaction and genetic interaction profiles, 569 nq is the number of genetic interaction profiles, and np is the number of bioprocesses in B 570 annotated from the nq genetic interaction profiles in G. 571
To predict perturbed biological processes, chemical-genetic interaction matrices for each 572 profile type a {α, β, γ} are first converted to matrices of compound-gene similarity scores and 573 then to matrices containing the sums of these compound-gene similarity scores for each 574 compound-process pair. Three different z-score/p-value matrix pairs are then computed for each 575 profile type a, two of which are derived from the control chemical-genetic interaction profile 576 types b
{β, γ} ("control-derived" z-scores/p-values) and one of which is derived by 577 randomizing the scores within each compound's vector of compound-gene similarity scores 578 ("within-compound" z-scores/p-values, denoted as δ). The z-score and p-value matrices across 579 all scoring approaches c {β, γ, δ} are then combined into a final z-score/p-value matrix pair 580 for each profile type a. The false discovery rate is estimated by comparing the rate of prediction 581 for the treatment profiles α against that of the control profiles b {β, γ} across a range of p-582 value thresholds. For the comparison of CG-TARGET to an enrichment-based approach, one 583 enrichment factor/p-value matrix pair replaces the final z-score/p-value matrix pair for each 584 profile type a, with the same false discovery rate calculations occurring afterward. 585
Resampled chemical-genetic interaction profiles. An nm x nγ matrix of resampled chemical-586 genetic interaction profiles Cγ is constructed such that interaction scores for each gene are 587 sampled randomly with replacement across the chemical-genetic interaction profiles. Assuming 588 that rand(x) is a function to randomly sample one value from the set of integers x in a uniformly 589 random fashion, and {1..nα} is the set of integers between and including 1 and nα, the interaction 590 score for the i th mutant in the j th resampled profile is denoted by: Ultimately, the different p-values and z-scores for each compound-process pair are combined 687 into one p-value and z-score for that pair. These scores are combined such that the largest (least 688 significant) p-value is chosen along with its associated z-score. If multiple p-values tie for the 689 largest value, then the one with the smallest associated z-score is chosen. As such, the resulting 690 combination of p-value and z-score represents the most conservative estimate of the strength and 691 significance of the prediction from compound to perturbed biological process. 692
To combine the p-values and z-scores, a matrix Psourcea for each profile type a {α, β, γ} 693 is first created to determine, for each compound-process pair, which p-value and z-score matrices 694 will contribute the final p-value and z-score. For each z-score/p-value scoring approach c {β, 695 γ, δ}, each entry of this matrix is denoted by: 696 Computing biological process enrichments. An enrichment-based method for predicting 705 biological processes perturbed by compounds was also implemented to provide an appropriate 706 baseline for assessing the performance of CG-TARGET. This enrichment-based method 707 computes biological process enrichment within the genes that contribute the top n out of nq 708 compound-gene similarity scores for each compound (from each compound-gene similarity score 709 matrix Xa for profile types a {α, β, γ}). Ultimately, two sets of matrices are computed, E(a,n) 710 and PE(a,n), which respectively contain the enrichment factor and hypergeometric p-value for each 711 compound and biological process pair. Enrichments were computed for n {10, 20, 50, 100, 712 200, 300, 400, 600, 800}.
First, a binary matrix X top (a,k) is derived from the matrix of compound-gene similarity scores Xa, 714 such that in each row, the positions corresponding to the top n scores are set to 1 and the 715 remaining positions are set to 0. This is denoted as: where B*,j is the column vector of the binary bioprocess matrix B containing gene annotations for 730 the j th bioprocess, ∑ B*,j is the number of genes annotated to the j th bioprocess, and hygeCDF(N, 731 K, n, k) is the cumulative hypergeometric distribution given a population size of N with K 732 success states and n draws with k observed successes. 733
Estimating the false discovery rate. The false discovery rates of the compound-process 734 predictions are estimated by comparing, using the entire range of observed p-values as 735 thresholds, the number of compounds with at least one bioprocess prediction against the number 736 of experimental controls and resampled profiles with at least one bioprocess prediction. We 737 compute a false discovery rate matrix FDRb for the treatment profiles α against each control 738 profile type b {β, γ}. This FDRb matrix is individually computed for the CG-TARGET-based 739 compound-process predictions as well as for each version of the enrichment-based compound-740 process predictions (using the p-value matrices PZ(a) and PE(a,n)); for simplicity, we do not change 741 the notation of FDRb to reflect if the false discovery rate values were computed on the output 742 from CG-TARGET or our baseline enrichment-based approach. 743
The first step in computing the false discovery rate is obtaining length na vectors ptopa that 744 contain the smallest p-value within each profile's bioprocess predictions, for each profile type a 745 {α, β, γ}. Additionally, the union of all observed p-values pall defines the universe of p-values 746 for which corresponding false discovery rates will be computed. Given p-value matrices Pa (PZ(a) 747 or PE(a,n) for one value of n) and a function sortAsc() that returns the input values sorted in 748 ascending order, the vectors ptopa and pall are given by: 749 We then compute a mapping from each observed p-value to its corresponding false discovery 753 rate, with mappings generated with respect to each control profile type b {β, γ}. First, a vector 754 of false discovery rates r * b is computed, each value corresponding to a p-value threshold in pall, by 755 dividing the fraction of treatment profiles with one or more bioprocess predictions that pass the 756 threshold by the fraction of control profiles that also pass the threshold. As the p-values in the 757 vector pall are monotonically increasing, it is desirable for the false discovery rate to increase 758 monotonically with the p-value. However, it is possible for the false discovery rate to decrease as 759 p-value increases (if the fraction of treatment profiles passing the threshold increases faster than 760 the fraction of control profiles passing the threshold), and thus we adjust each false discovery 761 rate value in the vector r * b to be the minimum of its current value or any value at a larger index to 762 generate a new vector rb (similar to the Benjamini-Hochberg procedure [43]). The final p-value 763 to false discovery rate mappings can be written as a function of the p-value p, with the procedure 764 to generate these mappings given by: Given this mapping of p-value to false discovery rate, the resulting matrices of false 771 discovery rates with respect to control profile types b
{β, γ} are given by: 772 ( †°¢ P ) 6,8 = l úùû(P) 2(Z Y ) 6,8 5 773 (Eqn. 17). 774
Computational evaluation of bioprocess predictions 775
Performance on simulated chemical-genetic interaction profiles. We generated a set of 776 simulated chemical-genetic interaction profiles derived from genetic interaction profiles [11] . 777
Each simulated chemical-genetic interaction profile was a query genetic interaction profile 778 augmented with noise sampled from a Gaussian distribution with a mean of 0 and a variance for 779 each array gene twice that of the same array gene in the genetic interaction dataset. Three 780 simulated profiles were generated based on each query gene, resulting in 4515 total profiles. 781
Because each simulated chemical-genetic interaction profile was derived from a query genetic 782 interaction profile, it inherited the gold-standard bioprocess annotations from its parent genetic 783 interaction profile in subsequent benchmarking efforts. 784
We then used CG-TARGET and each top-n enrichment method to predict perturbed 785 bioprocesses for this set of 4515 simulated chemicals x 289 deletion mutants. For each simulated 786 chemical, its top bioprocess prediction was compared to the set of inherited gold-standard 787 bioprocess annotations, counting as a true positive if the top prediction matched an existing 788 annotation and a false positive if it did not. Precision-recall curves were then generated by 789 sorting the list of each simulated chemical's top bioprocess predictions (p-value ascending, z-790 score or enrichment factor descending) and computing the precision (true positives / (true 791 positives + false positives)) and recall (true positives) at each point in this list. 792
Performance on gold-standard compound-bioprocess annotations. The predicted perturbed 793 bioprocesses for each of the gold-standard compounds were sorted, first in ascending order by 794 their p-value and then descending order by their z-score (for CG-TARGET) or enrichment factor 795 (top-n enrichment), and the rank of each compound's gold-standard bioprocess annotation was 796 recorded. To assess the significance of each rank, each pair of p-value and z-score was randomly 797 assigned to a new bioprocess (without replacement), the lists re-ordered, and the ranks of each 798 compound's target bioprocess re-computed. The empirical p-value for each gold-standard 799 compound-process pair was computed as the number of times the rank from the shuffled 800 bioprocesses achieved the same or better rank as the observed rank, divided by the number of 801 randomizations. These randomizations were also used as a baseline against which to compare the 802 number of compounds (out of 35) that achieved a given rank, as seen in Figs 3 and S1; the 803 displayed ribbons were generated by calculating, for each rank, the relevant percentiles on the 804 distribution of compounds with randomized predictions that achieved that rank. The "effective 805 rank" of a compound's gold-standard bioprocess annotation was determined as the minimum 806 rank of any bioprocess term with which it possessed sufficient gene annotation similarity 807 (overlap index ≥ 0.4, where the overlap index of two sets is defined as the size of the intersection 808 divided by the size of the smaller set). 809
Characterizing performance with respect to individual bioprocess terms. For each 810 propagated GO biological process term used for bioprocess prediction, we gathered all 811 predictions to that term across the 4515 simulated chemical-genetic interaction profiles and 812 sorted the predictions in ascending order by p-value and then in descending order by z-score. The 813 area under the precision-recall curve (AUPR) was calculated across this sorted list of simulated 814 compounds, with a true positive defined as the occurrence of a simulated compound that was 815 annotated to the bioprocess (via the simulated compound's parent gene). To obtain the final 816 evaluation statistic for each GO term, this AUPR was divided by the AUPR of a random 817 classifier, which is equal to the number of true positives divided by the total number of simulated 818
compounds. 819
Assessing the compatibility of chemical-genetic and genetic interaction profiles 820 Analysis of bioprocess prediction drivers in chemical-genetic interaction data. Given a 821 compound and a predicted bioprocess, a profile of "importance scores" describes the 822 contribution of each gene mutant to that compound's bioprocess prediction. To obtain this score, 823 a mean genetic interaction profile was first computed across all L2-normalized genetic interaction 824 profiles annotated to the biological process for which the inner product with the compound's 825 chemical-genetic interaction profile was 2 or greater. The importance score profile was then 826 obtained by taking the Hadamard product (elementwise multiplication) between this mean 827 genetic interaction profile and the compound's chemical-genetic interaction profile.
Overrepresentation analyses of gene mutants with strong chemical-genetic and/or genetic 829
interactions. After restricting the data to the top biological process prediction for each 830 compound, gene mutants that possessed strong, negative chemical-genetic interaction scores (z-831 score < -5) were assessed for overrepresentation with respect to the number of times they did not 832 contribute (importance score within ±0.1) to a compound's top bioprocess prediction. 833
Specifically, the number of times each strain occurred inside and outside the region described 834 above (grey box in Figure 5 ) was compared to the number of times all strains occurred inside and 835 outside the region using a hypergeometric test, using all strains with interaction z-scores < -5 as 836 the background set. Details on the genes overrepresented in this region are given in Table S2 . 837
Experimental validation of compound-bioprocess predictions
838 Phenotypic analysis of cell cycle progression. To examine the effect of compounds on arresting 839 cells in G2/M phase, we looked for differences in budding index and cell DNA content between 840 compounds predicted to perturb the cell cycle versus negative control compounds. Seventeen 841 compounds with high-confidence predictions to the bioprocess term "mitotic spindle assembly 842 checkpoint" and strong negative chemical-genetic interactions with PAT1 and LSM6 (a common 843 signature for compounds with this bioprocess prediction) were selected for validation. 844
Additionally, ten bioactive (growth inhibition 50-80% compared to DMSO control) compounds 845 with high confidence predictions (false discovery rate ≤ 25%) to bioprocess terms not related to 846 cell cycle signaling and progression were selected as negative controls. Two compounds 847 predicted to perturb "cell cycle phase" were also tested in these experiments. All compounds 848 were tested at a concentration of 10 µg/mL, which was also the concentration used for chemical 849 genomic screening [11] . 850
To quantify budding index, logarithmically-growing pdr1∆pdr3∆snq2∆ cells were 851 transferred to fresh galactose-containing medium (YPGal) containing compounds and incubated 852 at 25 °C for 4 hours. The budding status of at least 200 cells was visually determined under the 853 microscope. The percentage of the budded cells in no compound or compound-treated samples 854 was counted. 855
For flow cytometry analysis, log phase pdr1∆pdr3∆snq2∆ cells were grown in YPGal media 856 in the presence or absence of a compound for 4 hours; they were then fixed in 70% ethanol for 857 containing RNase A (0.25 mg/mL in 50 mM Tris, pH 7.5) for 1.5 hours. Cells were further 859 incubated in 20 µl of 20 mg/ml proteinase K at 50 °C for 1 hour. Samples were then stained with 860 propidium iodide, briefly sonicated, and measured using FACSCalibur ver 2.0 (Becton 861 Dickinson, CA, USA). 862
The proportions of predicted active compounds and negative controls with positive 863 phenotypic results were compared using the prop.test function in R to assess significance. 864
Inhibition of tubulin polymerization. In vitro tubulin polymerization assays using a 865 fluorescent-based porcine tubulin polymerization assay (Cytoskeleton, BK011P) were performed 866 following manufacturer specifications. Compounds were tested at a concentration of 10 µg/ml 867 (with the exception of assay controls), which was identical to the concentration used for 868 chemical genomic screening. All ten compounds predicted to perturb "tubulin complex 869
assembly" with the minimum estimated false discovery rate (FDR < 1%) were selected for 870 testing. Twelve compounds with predictions of false discovery rate ≤ 25% to any bioprocess 871 except those related to chromosome segregation, kinetochore, spindle assembly, and 872 microtubules were randomly selected as negative controls. 873
The degree of tubulin polymerization inhibition was summarized in a single Vmax statistic for 874 each compound treatment replicate. The Vmax for each compound's fluorescence time-course was 875 calculated as the maximum change in fluorescence between consecutive time points, which were 876 measured at 1-minute intervals. Three batches of experiments were performed in total (resulting 877 in N ≥ 2 for each compound), and we normalized the Vmax values in each batch by subtracting the 878 difference between that batch's mean DMSO (solvent control) Vmax and the overall mean DMSO 879
Vmax. To determine if the tubulin-predicted compounds inhibited polymerization to a 880 significantly greater degree than the controls, we calculated the mean of the normalized Vmax 881 values for each compound and performed a one-sided Wilcoxon rank-sum to test for a difference 882 in the ranks of these values between the two classes of compounds. 883
Chemical structure similarities between each pair of compounds selected for tubulin 884 polymerization validation were obtained by first computing an all-shortest-paths fingerprint with 885 path length 8 for each compound [44] . Similarities were computed on the fingerprints using the 886 Braun-Blanquet similarity coefficient, which is defined as the size of the intersection divided by 887 the size of the larger set. In a recent study, this combination of structure descriptor and similarity 888 coefficient performed well when evaluated globally on our entire chemical-genetic interaction 889 no role in study design, data collection and analysis, decision to publish, or preparation of the 912 manuscript. 913 Table 1 . The number of compounds discovered at selected false discovery rates upon application of CG-TARGET to data from two large-scale chemical-genetic interaction screens. The "RIKEN" screen consisted of 8418 total compounds from the RIKEN Natural Product Depository, and the "NCI/NIH/GSK" consisted of 3565 compounds across 6 chemical compound collections from the National Cancer Institute, National Institutes of Health, and GlaxoSmithKline. Table 2 . Evaluation of predictions made by CG-TARGET, and comparison to a baseline enrichment approach, for literature-derived, gold-standard compound-process annotations. The target bioprocess rank was determined by its position in the list of all bioprocess predictions for each gold-standard compound, with the significance computed empirically by shuffling the bioprocesses and re-computing the rank (bold p-values indicate significance, p < 0.05). Asterisks indicate cases in which the false discovery rate of the gold-standard compound-process prediction was less than 25%.
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